Febrile Clinical Trial - A Clinical Data Collection Study of Verily Patch

Phase 1: Researchers test a new drug or treatment in a small group of people for the first time to evaluate its safety, determine a safe dosage range, and identify side effects.
Phase 2: The drug or treatment is given to a larger group of people to see if it is effective and to further evaluate its safety.
Phase 3: The drug or treatment is given to large groups of people to confirm its effectiveness, monitor side effects, compare it to commonly used treatments, and collect information that will allow the drug or treatment to be used safely.
Phase 4: Studies are done after the drug or treatment has been marketed to gather information on the drug's effect in various populations and any side effects associated with long-term use.

Clinical Trial Summary

This is a single center, prospective, non-randomized prospective observational data collection study of the Verily Patch. The Verily Patch is an investigational wearable, continuous temperature sensor which will be evaluated against reference oral and axillary temperature measurements to support development activities for the Verily Patch.

See also
Status	Clinical Trial	Phase
Completed	`NCT01714570` - Piperacillin/Tazobactam for Empirical Therapy of Febrile Neutropenia	N/A
Completed	`NCT00913042` - Assessment of New Blood Culture Methods on the Microbiological Documentation of Febrile Neutropenia	N/A
Active, not recruiting	`NCT06353490` - The Clinical Performance Validation of Electronic Thermometer and Infrared Thermometers	N/A

NCT number	NCT04727801
Study type	Observational
Source	Verily Life Sciences LLC
Contact
Status	Terminated
Phase
Start date	March 11, 2021
Completion date	May 25, 2021

A Clinical Data Collection Study of Verily Patch

Clinical Trial Summary

Clinical Trial Description

Study Design

Related Conditions & MeSH terms